メトリジン錠2mg、メトリジンD錠2mg
項目別副作用発現頻度及び臨床検査値異常一覧
総症例9,156例中、121例（1.32%）154件に副作用が認められた。その主なものは、頭痛14件、悪心13件、腹痛12件であった。〔メトリジン錠2mg再審査終了時〕
| 承認時迄の調査 | 製造販売後調査＊ | 総 計 | |||||
| 調査症例数 | 784 | 8372 | 9156 | ||||
| 副作用発現症例数(％) | 45 | (5.74) | 76 | (0.91) | 121 | (1.32) | |
| 副作用発現件数(％) | 51 | (6.51) | 103 | (1.23) | 154 | (1.68) | |
| 副作用の種類 | 副作用発現件数（％） | ||||||
| 皮膚・皮膚付属器障害 | 11 | (1.40) | 10 | (0.12) | 21 | (0.23) | |
| 発疹 | 4 | (0.51) | 4 | (0.05) | 8 | (0.09) | |
| 蕁麻疹 | 1 | (0.13) | 1 | (0.01) | 2 | (0.02) | |
| そう痒感 | 2 | (0.26) | 1 | (0.01) | 3 | (0.03) | |
| 皮膚炎 | 1 | (0.01) | 1 | (0.01) | |||
| 立毛感 | 3 | (0.38) | 3 | (0.04) | 6 | (0.07) | |
| 発赤 | 1 | (0.13) | 1 | (0.01) | |||
| 中枢・末梢神経系障害 | 12 | (1.53) | 18 | (0.22) | 30 | (0.33) | |
| 肩こり | 1 | (0.13) | 1 | (0.01) | 2 | (0.02) | |
| 筋強剛 | 1 | (0.13) | 1 | (0.01) | |||
| 痙攣 | 1 | (0.13) | 1 | (0.01) | |||
| もうろう状態 | 1 | (0.01) | 1 | (0.01) | |||
| 手指冷感 | 1 | (0.01) | 1 | (0.01) | |||
| 頭痛（頭重を含む） | 9 | (1.15) | 5 | (0.06) | 14 | (0.15) | |
| 下肢しびれ(感) | 2 | (0.02) | 2 | (0.02) | |||
| めまい | 7 | (0.08) | 7 | (0.08) | |||
| 末梢神経障害 | 1 | (0.01) | 1 | (0.01) | |||
| 自律神経系障害 | 2 | (0.26) | 5 | (0.06) | 7 | (0.08) | |
| 高血圧（血圧上昇を含む） | 5 | (0.06) | 5 | (0.05) | |||
| 発汗亢進 | 2 | (0.26) | 2 | (0.02) | |||
| 精神障害 | 4 | (0.51) | 8 | (0.10) | 12 | (0.13) | |
| 眠気 | 1 | (0.13) | 4 | (0.05) | 5 | (0.05) | |
| 幻覚 | 1 | (0.13) | 1 | (0.01) | 2 | (0.02) | |
| いらいら感 | 1 | (0.13) | 1 | (0.01) | |||
| 不穏 | 1 | (0.01) | 1 | (0.01) | |||
| 不眠（症) | 2 | (0.02) | 2 | (0.02) | |||
| 妄想 | 1 | (0.13) | 1 | (0.01) | |||
| 消化管障害 | 15 | (1.91) | 26 | (0.31) | 41 | (0.45) | |
| 悪心 | 6 | (0.77) | 7 | (0.08) | 13 | (0.14) | |
| 嘔吐 | 1 | (0.13) | 3 | (0.04) | 4 | (0.04) | |
| 下痢 | 2 | (0.02) | 2 | (0.02) | |||
| 口内炎 | 2 | (0.26) | 2 | (0.02) | |||
| 胃もたれ感 | 1 | (0.13) | 1 | (0.01) | |||
| 胸やけ | 1 | (0.01) | 1 | (0.01) | |||
| 食欲減退 | 1 | (0.01) | 1 | (0.01) | |||
| 腹痛 | 2 | (0.26) | 10 | (0.12) | 12 | (0.13) | |
| 便秘 | 1 | (0.13) | 1 | (0.01) | 2 | (0.02) | |
| 腹部膨満感 | 2 | (0.26) | 2 | (0.02) | |||
| 排便回数増加 | 1 | (0.01) | 1 | (0.01) | |||
| 心拍数・心リズム障害 | 1 | (0.13) | 4 | (0.05) | 5 | (0.05) | |
| 心室性期外収縮 | 1 | (0.13) | 1 | (0.01) | |||
| 動悸 | 4 | (0.05) | 4 | (0.04) | |||
| 肝臓 | 2 | (0.26) | 10 | (0.12) | 12 | (0.13) | |
| 肝機能障害 | 6 | (0.07) | 6 | (0.07) | |||
| ALT上昇 | 1 | (0.13) | 2 | (0.02) | 3 | (0.03) | |
| AST上昇 | 2 | (0.02) | 2 | (0.02) | |||
| Al-P上昇 | 1 | (0.13) | 1 | (0.01) | |||
| 血液 | 0 | (0.00) | 4 | (0.05) | 4 | (0.04) | |
| 赤血球減少 | 1 | (0.01) | 1 | (0.01) | |||
| ヘマトクリット値減少 | 1 | (0.01) | 1 | (0.01) | |||
| 白血球減少(症) | 1 | (0.01) | 1 | (0.01) | |||
| 血小板減少(症) | 1 | (0.01) | 1 | (0.01) | |||
| 泌尿器系障害 | 1 | (0.13) | 1 | (0.01) | 2 | (0.02) | |
| 頻尿 | 1 | (0.13) | 1 | (0.01) | 2 | (0.02) | |
| その他 | 3 | (0.38) | 17 | (0.20) | 20 | (0.22) | |
| 悪寒 | 3 | (0.04) | 3 | (0.03) | |||
| 顔面浮腫 | 1 | (0.01) | 1 | (0.01) | |||
| 倦怠感 | 3 | (0.04) | 3 | (0.03) | |||
| 浮腫 | 1 | (0.01) | 1 | (0.01) | |||
| ほてり感 | 3 | (0.38) | 6 | (0.07) | 9 | (0.10) | |
| 脱力(感) | 1 | (0.01) | 1 | (0.01) | |||
| BUN上昇 | 1 | (0.01) | 1 | (0.01) | |||
| 耳閉感 | 1 | (0.01) | 1 | (0.01) | |||
*製造販売後調査〔使用成績調査報告（H1.3.31～H7.3.30）、特別調査（H5.9.1～H6.8.31）〕
